Eli Lilly on Wednesday said its experimental pill outperformed Novo Nordisk 's own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes.

The late-stage study comes as Eli Lilly's pill inches closer to becoming another needle-free alternative in the blockbuster market for GLP-1s, without dietary restrictions. But it may be too soon to establish a clear winner in the pill space, as there is no data comparing Eli Lillly's drug with a higher dose of Novo Nordisk's pill in patients with obesity.

Eli Lilly said its pill, orforglipron, was superior at the trial's main goal of lowering blood sugar levels at 52 weeks compared to Novo Nordisk's oral semaglutide. The highest dose of orforglipron helped lower hemoglobin A1c — a me

See Full Page